bluebird bio Announces First Patient Transplanted In Phase 1/2 Northstar Study For The Treatment Of Beta-Thalassemia
3/27/2014 9:11:00 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq:BLUE) a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced that the first subject with beta-thalassemia major has been enrolled in its phase 1/2 Northstar Study (HGB-204) in the United States and has undergone infusion with bluebird bio’s LentiGlobin drug product in an autologous hematopoietic stem cell transplantation.
Help employers find you! Check out all the jobs and post your resume.
comments powered by